TPST — Tempest Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $23.72m
- -$0.19m
Annual income statement for Tempest Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 36 | 27 | 34.6 | 29.2 | 42 |
| Operating Profit | -36 | -27 | -34.6 | -29.2 | -42 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.4 | -28.3 | -35.7 | -29.5 | -41.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -36.4 | -28.3 | -35.7 | -29.5 | -41.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -36.4 | -28.3 | -35.7 | -29.5 | -41.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -36.4 | -28.3 | -35.7 | -29.5 | -41.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -376 | -97.1 | -40.2 | -24.9 | -19.5 |